Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [ID6452]

  • In development
  • GID-TA11557
  • Expected publication date: 

31253-Darolutamide-Androgen-Deprivation-Therapy-for-Prostate-Cancer-V1.0-APR2024-NON-CONF.pdf (nihr.ac.uk)